Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors

Bone marrow involvement by lymphoproliferative disorders after renal transplantation: PTLD. Int. Survey

“…[31] According to the Ann Arbor staging system for non-Hodgkin's lymphoma, BM involvement at diagnosis defines stage IV disease, [32] and is associated with a more ominous clinical course. [33,34] Our data shows that BM involvement by neoplastic lymphomatoid cells in PTLD, as mentioned for that in non-transplant era, is associated with an inferior outcome. Moreover, we found that BM PTLD lesions were more likely to be monomorphic than benign features with no case in the early lesion category, although the difference did not reach significance level.…”

Untitled

“…Similar to our study, Montanari and coworkers showed less bone marrow involvement at patients with extranodal PTLD compared with patients with nodal PTLD. 1 The underlying pathophysiologic mechanisms responsible for this inverse relation between extranodal and bone marrow involvement are unclear and require further investigation.…”

“…The monomorphic PTLDs have been subclassified, based on morphologic, immuno phenotypic, genetic, and clinical features, into diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, plasma cell myeloma, plasmacytoma-like lesions, and various subtypes of T-and natural-killer-cell lymphomas. 1,2 Recommendations for staging PTLD currently are based on Ann Arbor clinical staging criteria. Bone marrow examination is an integral part of the Ann Arbor staging system for all lymphoproliferative malignancies.…”

Numb Chin Syndrome as the Initial Presentation of Posttransplant Lymphoproliferative Disorder

“…PTLD accounts for about 20% of all malignancies following solid organ transplantation (18,19). Th ese cancers involve mostly B-cell components, but may also involve T cells or rarely natural killer (NK) cells (20). Th e cause is related to concurrent immunosuppression and EBV viremia (21).…”